| (688247)"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Obtaining the INVIMA Approval Number for Posaconazole Enteric-coated Tablets in Colombia | Nov 13, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| (688247)"SINOTHERAPEUTICS INC."Report for Q3 2026 | Oct 29, 2026 | Quarterly report | Shanghai Stock Exchange |
|---|
| (688247)"SINOTHERAPEUTICS INC."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction | Oct 29, 2026 | Results | Shanghai Stock Exchange |
|---|
| (688247)"SINOTHERAPEUTICS INC."Announcement on Release of Pledge of Certain Shares Held by Shareholder | Oct 20, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| (688247)"SINOTHERAPEUTICS INC."Announcement on Implementation of Dividend Distribution for the First Half of 2026 | Oct 17, 2026 | Dividend | Shanghai Stock Exchange |
|---|
| (688247)"SINOTHERAPEUTICS INC."Announcement on Completion of Transfer of Certain Shares under Gratuitous Donation by Shareholder | Oct 16, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Announcement on Change of Signing Certified Public Accountant | Sep 10, 2026 | Management or board change | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026 | Aug 27, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Announcement on Using Certain Idle Raised Funds for Cash Management | Aug 4, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement | Aug 3, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Approval of Posaconazole Enteric-coated Tablets via the EU Decentralised Procedure (DCP) | Jul 24, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New Specification | Jul 13, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| "SINOTHERAPEUTICS INC."Announcement on Abnormal Fluctuations in Stock Trading | Jul 2, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Implementation of Dividend Distribution for 2025 | Jun 21, 2026 | Dividend | Shanghai Stock Exchange |
|---|
| Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Shareholding Reduction | Jun 10, 2026 | Results | Shanghai Stock Exchange |
|---|
| Senior Management Member" -- Announcement on Completing Term Change and Election of the Board of Directors and Appointing Senior Management Members and Securities Affairs Representative, as well as Departure of Core Technical Personnel | May 28, 2026 | Management or board change | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining the Colombian INVIMA Approval for Bupropion Hydrochloride Extended-release Tablets | May 25, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Notice on Convening the 2025 Annual General Meeting | Apr 29, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference | Apr 28, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1% and 5% Scale | Apr 14, 2026 | Ownership change notice | Shanghai Stock Exchange |
|---|
| Announcement on Resolutions of the 25th Meeting of the 2nd Board of Directors | Apr 1, 2026 | Meeting outcome | Shanghai Stock Exchange |
|---|
| Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2025 Restricted Stock Incentive Plan | Mar 26, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Sinotherapeutics® Tomato Red Grape Seed Extract Tablets Obtaining the Domestic Health Food Registration Certificate | Mar 17, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Notice on Convening the 1st Extraordinary General Meeting in 2026 | Mar 16, 2026 | Meeting notice | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Clinical Trial Applications for Collaborative Product Enzalutamide Tablets Approved by China NMPA | Mar 13, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft) | Mar 10, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 Tablets | Mar 2, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Preliminary Earnings Estimate for 2025 | Feb 27, 2026 | Results | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug Procurement | Feb 10, 2026 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares | Feb 9, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Provision for Asset Impairment for 2025 | Jan 29, 2026 | Results | Shanghai Stock Exchange |
|---|
| Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft) | Jan 14, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPA | Jan 6, 2026 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Appointment of Senior Management Members | Dec 25, 2025 | Management or board change | Shanghai Stock Exchange |
|---|
| Announcement on Postponement of Investment Projects Financed by Raised Funds | Dec 12, 2025 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance Catalog | Dec 8, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025 | Nov 4, 2025 | Meeting notice | Shanghai Stock Exchange |
|---|
| Report for Q3 2025 | Oct 30, 2025 | Quarterly report | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug Procurement | Oct 29, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Indicative Announcement on Equity Change of Shareholding Reduction by Shareholder with Over 5% Shares to Less than 5% | Oct 22, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Changing Signatory Certified Public Accountant | Oct 21, 2025 | Management or board change | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Sitagliptin and Metformin Hydrochloride Sustained-release Tablets | Oct 20, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares | Oct 16, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Implementation of Semi-annual Dividend Distribution for 2025 | Oct 14, 2025 | Dividend | Shanghai Stock Exchange |
|---|
| Announcement on Pledge of Partial Shares by Shareholders with Over 5% of Shares | Oct 10, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Increasing Estimated Amount of Daily Related Party Transactions in 2025 | Sep 30, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining Marketing Approval by the National Medical Products Administration for the New Strength of Sitagliptin and Metformin Hydrochloride Sustained-release Tablets | Sep 26, 2025 | Operations update | Shanghai Stock Exchange |
|---|
| Announcement on Cancellation of Some Accounts for Raised Funds | Sep 23, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Attending Semi-annual Collective Performance Briefing for Enterprises in Biological Products and CXO Industries on SSE STAR Market 2025 | Sep 5, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Special Report on Semi-annual Deposit and Use of Raised Funds in 2025 | Aug 22, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering | Aug 17, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Using Partial Idle Raised Funds for Cash Management | Aug 8, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining EU GMP Certification by the Wholly-owned Subsidiary | Jul 17, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Enzalutamide Tablets | Jun 26, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Implementation of Dividend Distribution for 2024 | Jun 22, 2025 | Dividend | Shanghai Stock Exchange |
|---|
| Announcement on Resolution of the 2024 Annual General Meeting | May 29, 2025 | Meeting notice | Shanghai Stock Exchange |
|---|
| Announcement on the Change of Investor Hotline | May 20, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets | May 12, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Changes in Some Directors, Senior Management Members, Financial Chief and Core Technical Personnel | May 5, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Canceling the Board of Supervisors and Amending the Articles of Association and Some Management Systems | Apr 29, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Pledge Release of Some Shares Held by Shareholders with Over 5% Shares | Mar 24, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Expiration of Plan of Shareholding Reduction by Shareholder with Over 5% Shares and Results of Shareholding Reduction | Mar 18, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1% | Mar 14, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Preliminary Earnings Estimate for 2024 | Feb 26, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on the Estimated Routine Related Party Transactions for 2025 | Feb 19, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Implementation Results of Shares Repurchase | Feb 18, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Progress in Repurchasing Shares | Feb 5, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Annual Earnings Preannouncement for 2024 | Jan 22, 2025 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Voluntary Disclosure of the Results of the Company's Products Participating in Centralized Volume-based Procurement of Drugs Organized by the State | Dec 13, 2024 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Plan of Shareholding Reduction by Shareholders with over 5% Shares | Nov 27, 2024 | Other filings | Shanghai Stock Exchange |
|---|
| Announcement on Convening the Q3 2024 Performance Briefing | Nov 25, 2024 | Other filings | Shanghai Stock Exchange |
|---|